Symbol	Name	# SSM Affected Cases in Cohort	# SSM Affected Cases Across the GDC	# CNV Gain	# CNV Loss	# Mutations	Annotations	Survival
MUC16	mucin 16, cell surface associated	284 / 382 (74.35%)	2,824 / 14,783	48 / 366 (13.11%)	60 / 366 (16.39%)	1,504	Cancer Gene Census	add to survival plot
BRAF	B-Raf proto-oncogene, serine/threonine kinase	188 / 382 (49.21%)	947 / 14,783	193 / 366 (52.73%)	10 / 366 (2.73%)	34	Cancer Gene Census	add to survival plot
LRP1B	LDL receptor related protein 1B	179 / 382 (46.86%)	1,742 / 14,783	61 / 366 (16.67%)	34 / 366 (9.29%)	367	Cancer Gene Census	add to survival plot
FAT3	FAT atypical cadherin 3	153 / 382 (40.05%)	1,392 / 14,783	31 / 366 (8.47%)	133 / 366 (36.34%)	279	Cancer Gene Census	add to survival plot
FAT4	FAT atypical cadherin 4	152 / 382 (39.79%)	1,394 / 14,783	36 / 366 (9.84%)	92 / 366 (25.14%)	305	Cancer Gene Census	add to survival plot
CSMD3	CUB and Sushi multiple domains 3	148 / 382 (38.74%)	1,945 / 14,783	158 / 366 (43.17%)	14 / 366 (3.83%)	262	Cancer Gene Census	add to survival plot
PTPRT	protein tyrosine phosphatase receptor type T	146 / 382 (38.22%)	793 / 14,783	152 / 366 (41.53%)	8 / 366 (2.19%)	201	Cancer Gene Census	add to survival plot
GRIN2A	glutamate ionotropic receptor NMDA type subunit 2A	130 / 382 (34.03%)	757 / 14,783	59 / 366 (16.12%)	43 / 366 (11.75%)	198	Cancer Gene Census	add to survival plot
NRAS	NRAS proto-oncogene, GTPase	117 / 382 (30.63%)	617 / 14,783	71 / 366 (19.40%)	67 / 366 (18.31%)	16	Cancer Gene Census	add to survival plot
FAM135B	family with sequence similarity 135 member B	115 / 382 (30.10%)	933 / 14,783	164 / 366 (44.81%)	19 / 366 (5.19%)	174	Cancer Gene Census	add to survival plot
DCC	DCC netrin 1 receptor	109 / 382 (28.53%)	737 / 14,783	43 / 366 (11.75%)	82 / 366 (22.40%)	154	Cancer Gene Census	add to survival plot
CNTNAP2	contactin associated protein 2	108 / 382 (28.27%)	796 / 14,783	187 / 366 (51.09%)	13 / 366 (3.55%)	133	Cancer Gene Census	add to survival plot
PREX2	phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 2	105 / 382 (27.49%)	684 / 14,783	140 / 366 (38.25%)	16 / 366 (4.37%)	154	Cancer Gene Census	add to survival plot
ROS1	ROS proto-oncogene 1, receptor tyrosine kinase	101 / 382 (26.44%)	596 / 14,783	19 / 366 (5.19%)	191 / 366 (52.19%)	135	Cancer Gene Census	add to survival plot
MECOM	MDS1 and EVI1 complex locus	96 / 382 (25.13%)	433 / 14,783	62 / 366 (16.94%)	58 / 366 (15.85%)	100	Cancer Gene Census	add to survival plot
PTPRB	protein tyrosine phosphatase receptor type B	95 / 382 (24.87%)	620 / 14,783	57 / 366 (15.57%)	49 / 366 (13.39%)	142	Cancer Gene Census	add to survival plot
PTPRD	protein tyrosine phosphatase receptor type D	91 / 382 (23.82%)	755 / 14,783	19 / 366 (5.19%)	229 / 366 (62.57%)	128	Cancer Gene Census	add to survival plot
COL3A1	collagen type III alpha 1 chain	87 / 382 (22.77%)	563 / 14,783	56 / 366 (15.30%)	40 / 366 (10.93%)	122	Cancer Gene Census	add to survival plot
ANK1	ankyrin 1	82 / 382 (21.47%)	686 / 14,783	88 / 366 (24.04%)	51 / 366 (13.93%)	115	Cancer Gene Census	add to survival plot
ERBB4	erb-b2 receptor tyrosine kinase 4	81 / 382 (21.20%)	658 / 14,783	50 / 366 (13.66%)	47 / 366 (12.84%)	98	Cancer Gene Census	add to survival plot
GRM3	glutamate metabotropic receptor 3	81 / 382 (21.20%)	514 / 14,783	162 / 366 (44.26%)	15 / 366 (4.10%)	104	Cancer Gene Census	add to survival plot
TP63	tumor protein p63	79 / 382 (20.68%)	395 / 14,783	59 / 366 (16.12%)	58 / 366 (15.85%)	86	Cancer Gene Census	add to survival plot
TRRAP	transformation/transcription domain associated protein	74 / 382 (19.37%)	718 / 14,783	165 / 366 (45.08%)	17 / 366 (4.64%)	91	Cancer Gene Census	add to survival plot
PTPRK	protein tyrosine phosphatase receptor type K	74 / 382 (19.37%)	407 / 14,783	23 / 366 (6.28%)	192 / 366 (52.46%)	90	Cancer Gene Census	add to survival plot
FAM47C	family with sequence similarity 47 member C	73 / 382 (19.11%)	619 / 14,783	0 / 366 (0.00%)	0 / 366 (0.00%)	92	Cancer Gene Census	add to survival plot
KMT2D	lysine methyltransferase 2D	72 / 382 (18.85%)	1,277 / 14,783	38 / 366 (10.38%)	66 / 366 (18.03%)	109	Cancer Gene Census	add to survival plot
CTNND2	catenin delta 2	71 / 382 (18.59%)	667 / 14,783	77 / 366 (21.04%)	59 / 366 (16.12%)	95	Cancer Gene Census	add to survival plot
MUC4	mucin 4, cell surface associated	71 / 382 (18.59%)	615 / 14,783	60 / 366 (16.39%)	56 / 366 (15.30%)	94	Cancer Gene Census	add to survival plot
NBEA	neurobeachin	68 / 382 (17.80%)	679 / 14,783	81 / 366 (22.13%)	70 / 366 (19.13%)	99	Cancer Gene Census	add to survival plot
KDR	kinase insert domain receptor	65 / 382 (17.02%)	485 / 14,783	52 / 366 (14.21%)	67 / 366 (18.31%)	78	Cancer Gene Census	add to survival plot
ZFHX3	zinc finger homeobox 3	64 / 382 (16.75%)	817 / 14,783	36 / 366 (9.84%)	90 / 366 (24.59%)	85	Cancer Gene Census	add to survival plot
ROBO2	roundabout guidance receptor 2	64 / 382 (16.75%)	648 / 14,783	72 / 366 (19.67%)	43 / 366 (11.75%)	80	Cancer Gene Census	add to survival plot
TP53	tumor protein p53	63 / 382 (16.49%)	4,851 / 14,783	24 / 366 (6.56%)	114 / 366 (31.15%)	55	Cancer Gene Census	add to survival plot
COL2A1	collagen type II alpha 1 chain	63 / 382 (16.49%)	395 / 14,783	41 / 366 (11.20%)	68 / 366 (18.58%)	79	Cancer Gene Census	add to survival plot
EPHA7	EPH receptor A7	62 / 382 (16.23%)	415 / 14,783	25 / 366 (6.83%)	172 / 366 (46.99%)	97	Cancer Gene Census	add to survival plot
CDH10	cadherin 10	62 / 382 (16.23%)	723 / 14,783	83 / 366 (22.68%)	59 / 366 (16.12%)	72	Cancer Gene Census	add to survival plot
MYH11	myosin heavy chain 11	61 / 382 (15.97%)	559 / 14,783	60 / 366 (16.39%)	46 / 366 (12.57%)	88	Cancer Gene Census	add to survival plot
KMT2A	lysine methyltransferase 2A	60 / 382 (15.71%)	670 / 14,783	13 / 366 (3.55%)	183 / 366 (50.00%)	68	Cancer Gene Census	add to survival plot
NF1	neurofibromin 1	60 / 382 (15.71%)	856 / 14,783	40 / 366 (10.93%)	65 / 366 (17.76%)	83	Cancer Gene Census	add to survival plot
SETBP1	SET binding protein 1	58 / 382 (15.18%)	517 / 14,783	41 / 366 (11.20%)	82 / 366 (22.40%)	73	Cancer Gene Census	add to survival plot
CARD11	caspase recruitment domain family member 11	57 / 382 (14.92%)	475 / 14,783	165 / 366 (45.08%)	20 / 366 (5.46%)	77	Cancer Gene Census	add to survival plot
RGS7	regulator of G protein signaling 7	57 / 382 (14.92%)	342 / 14,783	181 / 366 (49.45%)	19 / 366 (5.19%)	46	Cancer Gene Census	add to survival plot
NACA	nascent polypeptide associated complex subunit alpha	56 / 382 (14.66%)	339 / 14,783	44 / 366 (12.02%)	59 / 366 (16.12%)	69	Cancer Gene Census	add to survival plot
FAT1	FAT atypical cadherin 1	55 / 382 (14.40%)	1,021 / 14,783	41 / 366 (11.20%)	96 / 366 (26.23%)	72	Cancer Gene Census	add to survival plot
USP6	ubiquitin specific peptidase 6	54 / 382 (14.14%)	340 / 14,783	31 / 366 (8.47%)	106 / 366 (28.96%)	63	Cancer Gene Census	add to survival plot
SPEN	spen family transcriptional repressor	54 / 382 (14.14%)	618 / 14,783	52 / 366 (14.21%)	64 / 366 (17.49%)	66	Cancer Gene Census	add to survival plot
KMT2C	lysine methyltransferase 2C	54 / 382 (14.14%)	1,038 / 14,783	181 / 366 (49.45%)	17 / 366 (4.64%)	70	Cancer Gene Census	add to survival plot
ARID2	AT-rich interaction domain 2	54 / 382 (14.14%)	520 / 14,783	39 / 366 (10.66%)	71 / 366 (19.40%)	57	Cancer Gene Census	add to survival plot
KIAA1549	KIAA1549	54 / 382 (14.14%)	454 / 14,783	196 / 366 (53.55%)	8 / 366 (2.19%)	72	Cancer Gene Census	add to survival plot
TNC	tenascin C	53 / 382 (13.87%)	514 / 14,783	27 / 366 (7.38%)	149 / 366 (40.71%)	71	Cancer Gene Census	add to survival plot
CDKN2A	cyclin dependent kinase inhibitor 2A	53 / 382 (13.87%)	563 / 14,783	14 / 366 (3.83%)	258 / 366 (70.49%)	32	Cancer Gene Census	add to survival plot
IL7R	interleukin 7 receptor	53 / 382 (13.87%)	314 / 14,783	75 / 366 (20.49%)	53 / 366 (14.48%)	58	Cancer Gene Census	add to survival plot
ALK	ALK receptor tyrosine kinase	52 / 382 (13.61%)	487 / 14,783	53 / 366 (14.48%)	52 / 366 (14.21%)	69	Cancer Gene Census	add to survival plot
EPHA3	EPH receptor A3	52 / 382 (13.61%)	510 / 14,783	68 / 366 (18.58%)	39 / 366 (10.66%)	56	Cancer Gene Census	add to survival plot
COL1A1	collagen type I alpha 1 chain	52 / 382 (13.61%)	379 / 14,783	86 / 366 (23.50%)	41 / 366 (11.20%)	67	Cancer Gene Census	add to survival plot
RUNX1T1	RUNX1 partner transcriptional co-repressor 1	52 / 382 (13.61%)	501 / 14,783	147 / 366 (40.16%)	16 / 366 (4.37%)	54	Cancer Gene Census	add to survival plot
A1CF	APOBEC1 complementation factor	52 / 382 (13.61%)	251 / 14,783	7 / 366 (1.91%)	190 / 366 (51.91%)	59	Cancer Gene Census	add to survival plot
NTRK3	neurotrophic receptor tyrosine kinase 3	52 / 382 (13.61%)	496 / 14,783	95 / 366 (25.96%)	32 / 366 (8.74%)	68	Cancer Gene Census	add to survival plot
RNF213	ring finger protein 213	52 / 382 (13.61%)	742 / 14,783	99 / 366 (27.05%)	47 / 366 (12.84%)	69	Cancer Gene Census	add to survival plot
CACNA1D	calcium voltage-gated channel subunit alpha1 D	52 / 382 (13.61%)	497 / 14,783	52 / 366 (14.21%)	65 / 366 (17.76%)	70	Cancer Gene Census	add to survival plot
FLT3	fms related receptor tyrosine kinase 3	51 / 382 (13.35%)	357 / 14,783	77 / 366 (21.04%)	70 / 366 (19.13%)	54	Cancer Gene Census	add to survival plot
LIFR	LIF receptor subunit alpha	50 / 382 (13.09%)	324 / 14,783	77 / 366 (21.04%)	51 / 366 (13.93%)	61	Cancer Gene Census	add to survival plot
SRGAP3	SLIT-ROBO Rho GTPase activating protein 3	49 / 382 (12.83%)	292 / 14,783	47 / 366 (12.84%)	69 / 366 (18.85%)	61	Cancer Gene Census	add to survival plot
GPC5	glypican 5	49 / 382 (12.83%)	333 / 14,783	88 / 366 (24.04%)	66 / 366 (18.03%)	53	Cancer Gene Census	add to survival plot
PRKCB	protein kinase C beta	49 / 382 (12.83%)	341 / 14,783	53 / 366 (14.48%)	46 / 366 (12.57%)	54	Cancer Gene Census	add to survival plot
MET	MET proto-oncogene, receptor tyrosine kinase	48 / 382 (12.57%)	343 / 14,783	181 / 366 (49.45%)	12 / 366 (3.28%)	56	Cancer Gene Census	add to survival plot
ZNF479	zinc finger protein 479	47 / 382 (12.30%)	383 / 14,783	160 / 366 (43.72%)	15 / 366 (4.10%)	49	Cancer Gene Census	add to survival plot
CTNNA2	catenin alpha 2	47 / 382 (12.30%)	648 / 14,783	55 / 366 (15.03%)	39 / 366 (10.66%)	54	Cancer Gene Census	add to survival plot
PTPRC	protein tyrosine phosphatase receptor type C	47 / 382 (12.30%)	482 / 14,783	179 / 366 (48.91%)	18 / 366 (4.92%)	57	Cancer Gene Census	add to survival plot
AKAP9	A-kinase anchoring protein 9	47 / 382 (12.30%)	650 / 14,783	162 / 366 (44.26%)	16 / 366 (4.37%)	55	Cancer Gene Census	add to survival plot
BMP5	bone morphogenetic protein 5	47 / 382 (12.30%)	258 / 14,783	121 / 366 (33.06%)	44 / 366 (12.02%)	49	Cancer Gene Census	add to survival plot
CYP2C8	cytochrome P450 family 2 subfamily C member 8	46 / 382 (12.04%)	173 / 14,783	10 / 366 (2.73%)	202 / 366 (55.19%)	50	Cancer Gene Census	add to survival plot
ZEB1	zinc finger E-box binding homeobox 1	46 / 382 (12.04%)	388 / 14,783	12 / 366 (3.28%)	171 / 366 (46.72%)	57	Cancer Gene Census	add to survival plot
BCL11A	BAF chromatin remodeling complex subunit BCL11A	46 / 382 (12.04%)	375 / 14,783	59 / 366 (16.12%)	43 / 366 (11.75%)	57	Cancer Gene Census	add to survival plot
VAV1	vav guanine nucleotide exchange factor 1	45 / 382 (11.78%)	274 / 14,783	43 / 366 (11.75%)	74 / 366 (20.22%)	48	Cancer Gene Census	add to survival plot
CAMTA1	calmodulin binding transcription activator 1	45 / 382 (11.78%)	469 / 14,783	53 / 366 (14.48%)	65 / 366 (17.76%)	57	Cancer Gene Census	add to survival plot
BIRC6	baculoviral IAP repeat containing 6	44 / 382 (11.52%)	739 / 14,783	54 / 366 (14.75%)	47 / 366 (12.84%)	55	Cancer Gene Census	add to survival plot
EGFR	epidermal growth factor receptor	44 / 382 (11.52%)	632 / 14,783	162 / 366 (44.26%)	16 / 366 (4.37%)	57	Cancer Gene Census	add to survival plot
FLT4	fms related receptor tyrosine kinase 4	44 / 382 (11.52%)	460 / 14,783	41 / 366 (11.20%)	99 / 366 (27.05%)	60	Cancer Gene Census	add to survival plot
RANBP2	RAN binding protein 2	43 / 382 (11.26%)	529 / 14,783	56 / 366 (15.30%)	37 / 366 (10.11%)	50	Cancer Gene Census	add to survival plot
CREBBP	CREB binding protein	42 / 382 (10.99%)	669 / 14,783	54 / 366 (14.75%)	74 / 366 (20.22%)	49	Cancer Gene Census	add to survival plot
NCOR2	nuclear receptor corepressor 2	42 / 382 (10.99%)	500 / 14,783	28 / 366 (7.65%)	75 / 366 (20.49%)	51	Cancer Gene Census	add to survival plot
APC	APC regulator of WNT signaling pathway	42 / 382 (10.99%)	1,064 / 14,783	35 / 366 (9.56%)	99 / 366 (27.05%)	45	Cancer Gene Census	add to survival plot
PRDM16	PR/SET domain 16	42 / 382 (10.99%)	366 / 14,783	52 / 366 (14.21%)	72 / 366 (19.67%)	64	Cancer Gene Census	add to survival plot
TET1	tet methylcytosine dioxygenase 1	42 / 382 (10.99%)	449 / 14,783	8 / 366 (2.19%)	193 / 366 (52.73%)	48	Cancer Gene Census	add to survival plot
CIITA	class II major histocompatibility complex transactivator	42 / 382 (10.99%)	314 / 14,783	61 / 366 (16.67%)	41 / 366 (11.20%)	45	Cancer Gene Census	add to survival plot
NRG1	neuregulin 1	41 / 382 (10.73%)	438 / 14,783	74 / 366 (20.22%)	67 / 366 (18.31%)	52	Cancer Gene Census	add to survival plot
CUX1	cut like homeobox 1	40 / 382 (10.47%)	485 / 14,783	163 / 366 (44.54%)	19 / 366 (5.19%)	54	Cancer Gene Census	add to survival plot
AFF3	AF4/FMR2 family member 3	40 / 382 (10.47%)	431 / 14,783	56 / 366 (15.30%)	35 / 366 (9.56%)	47	Cancer Gene Census	add to survival plot
WNK2	WNK lysine deficient protein kinase 2	40 / 382 (10.47%)	446 / 14,783	17 / 366 (4.64%)	159 / 366 (43.44%)	50	Cancer Gene Census	add to survival plot
SALL4	spalt like transcription factor 4	40 / 382 (10.47%)	368 / 14,783	159 / 366 (43.44%)	5 / 366 (1.37%)	46	Cancer Gene Census	add to survival plot
PDE4DIP	phosphodiesterase 4D interacting protein	39 / 382 (10.21%)	423 / 14,783	166 / 366 (45.36%)	15 / 366 (4.10%)	45	Cancer Gene Census	add to survival plot
SLC34A2	solute carrier family 34 member 2	39 / 382 (10.21%)	247 / 14,783	46 / 366 (12.57%)	62 / 366 (16.94%)	44	Cancer Gene Census	add to survival plot
SMARCA4	SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4	39 / 382 (10.21%)	558 / 14,783	45 / 366 (12.30%)	61 / 366 (16.67%)	45	Cancer Gene Census	add to survival plot
POLQ	DNA polymerase theta	39 / 382 (10.21%)	520 / 14,783	56 / 366 (15.30%)	57 / 366 (15.57%)	44	Cancer Gene Census	add to survival plot
CDH17	cadherin 17	39 / 382 (10.21%)	261 / 14,783	148 / 366 (40.44%)	16 / 366 (4.37%)	42	Cancer Gene Census	add to survival plot
PDGFRA	platelet derived growth factor receptor alpha	38 / 382 (9.95%)	432 / 14,783	50 / 366 (13.66%)	65 / 366 (17.76%)	43	Cancer Gene Census	add to survival plot
ZNF331	zinc finger protein 331	38 / 382 (9.95%)	205 / 14,783	46 / 366 (12.57%)	48 / 366 (13.11%)	42	Cancer Gene Census	add to survival plot
FGFR2	fibroblast growth factor receptor 2	37 / 382 (9.69%)	357 / 14,783	9 / 366 (2.46%)	205 / 366 (56.01%)	44	Cancer Gene Census	add to survival plot
BRCA2	BRCA2 DNA repair associated	36 / 382 (9.42%)	555 / 14,783	81 / 366 (22.13%)	67 / 366 (18.31%)	42	Cancer Gene Census	add to survival plot